GP 531 / Teva - LARVOL DELTA

Exploring the Enzymatic Activity of Depolymerase gp531 from Klebsiella pneumoniae jumbo phage RaK2. (PubMed, Virus Res) - "Additionally, we demonstrated that gp531's activity is not affected by CPS acetylation, which is influenced by the growth conditions of the bacterial culture. Overall, our findings provide valuable insights into the enzymatic activity of the first characterized depolymerase targeting the capsule of the clinically relevant K54 serotype of K. pneumoniae."

Journal • Infectious Disease • Pneumonia

Insights into the Alcyoneusvirus Adsorption Complex. (PubMed, Int J Mol Sci) - "We show that two of these proteins, gp098 and gp531, are essential for attaching to Klebsiella pneumoniae KV-3 cells: gp531 is an active depolymerase that recognizes and degrades the capsule of this particular host, while gp098 is a secondary receptor-binding protein that requires the coordinated action of gp531. Finally, we demonstrate that RaK2 long tail fibers consist of nine TFPs, seven of which are depolymerases, and propose a model for their assembly."

Journal • Infectious Disease • Pneumonia

[VIRTUAL] ViCardia Therapeutics Inc. (BIO 2021) - "ViCardia Therapeutics Inc., a privately held company founded in 2017, based in San Francisco, is entering Phase 2 with GP531, a potent, long-lasting infusion therapy that treats mitochondrial dysfunction in acute heart failure. ViCardia is led by a highly experienced management team, board of directors and board of scientific advisors with extensive experience in treating chronic and acute heart failure and conducting cardiovascular research."

Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders